Treating New Learning and Memory Deficits in Progressive Multiple Scle
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
What it found
We found no results in the registry or in papers.
This trial finished 9 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Memory retraining exercises
Placebo
- Placebo control memory exercises
What it measured
Main measures
Change in scores on standardized neuropsychological tests of memory
Scores will be assessed at three time-points: Baseline (week 1), immediately post-intervention (week 7) and 3 months post-intervention
Thinking and memory
Other measures (3)
Change in scores on self-report of emotional functioning, measured via questionnaire
Scores will be assessed at three time-points: Baseline (week 1), immediately post-intervention (week 7) and 3 months post-intervention
Change in scores on self-report of memory functioning, measured via questionnaire
Scores will be assessed at three time-points: Baseline (week 1), immediately post-intervention (week 7) and 3 months post-intervention
Thinking and memoryChange in scores on self-report of quality of life, measured via questionnaire
Scores will be assessed at three time-points: Baseline (week 1), immediately post-intervention (week 7) and 3 months post-intervention
Quality of life (reported by participants)
Who could take part
Progressive MS · 30 to 59
Show the full criteria
Inclusion criteria
* between the ages of 30 and 59 * diagnosed with Progressive Multiple Sclerosis * have visual acuity of better then 20/60 in worse eye
Exclusion criteria
* has a prior stroke or neurological injury/disease (brain tumor, epilepsy, traumatic brain injury). * has a history of psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis). * currently taking medications such as: steroids, benzodiazepines, and neuroleptics. . * difficulty with vision, eyesight worse then 20/60, or has diminished sight in visual field, double vision, or nystagmus.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study is a double-blind placebo-controlled randomized clinical trial (RCT) to provide Class I evidence in support of or in refute of the efficacy of the modified Story Memory Technique (mSMT) in persons with progressive MS, with outcome measured through three mechanisms: (1) a traditional neuropsychological evaluation (NPE) (2) an assessment of global functioning (AGF) examining the impact of the treatment on daily activities, and (3) an optional functional magnetic resonance imaging (fMRI) scan.
Loading reviews and guidelines…
History
Started
Nov 2014
Main results due
Apr 2017
Finished
Apr 2017